Company intelligence / Profile preview

Qubist Molecular Design

Parkville, Victoria, Australiaqubist.bio ↗

Ownership: Private
Development stage: Other

Overview

Qubist Molecular Design was an Australian biotechnology company specializing in computational drug design and molecular modeling. Founded in 2009 by Professor Andrew Wilks and colleagues, the company utilized quantum chemistry and advanced optimization algorithms to support the discovery of novel small molecule therapeutics. Notably, the company's modeling expertise contributed to the development of momelotinib (Ojjaara), a JAK inhibitor approved for myelofibrosis. In 2024, Qubist Molecular Design merged with Presagen to form Qubigen, an AI-driven drug discovery firm that combines federated AI with quantum chemistry.

Therapeutic areas: ImmunologyHematologyOncology
Modalities: Small molecule
Industry: Drug Discovery Services

Partnerships

CytopiaSYN|thesis Med ChemMonash Institute of Pharmaceutical SciencesBioproton

Beyond the preview

Go deeper on Qubist Molecular Design.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qubist Molecular Design.